Cutting-edge stem cell therapy proves safe, but will it ever be effective? – Science Magazine
Science Magazine |
Cutting-edge stem cell therapy proves safe, but will it ever be effective?
Science Magazine It’s official: The first use of induced pluripotent stem (iPS) cells in a human has proved safe, if not clearly effective. Japanese researchers reported in this week’s issue of The New England Journal of Medicine ( NEJM ) that using the cells to … Experimental stem cell treatment stabilizes macular degenerationCNN 3 cases of blindness raise questions about stem cell clinicsSan Francisco Chronicle Doctors say unproven stem cell treatment blinded 3 womenABC News CBS News –STAT –The Independent –Bascom Palmer Eye Institute all 43 news articles » |
|
Vision saved by first induced pluripotent stem cell treatment
New Scientist A woman in her 80s has become the first person to be successfully treated with induced pluripotent stem (iPS) cells. A slither of laboratory-made retinal cells has protected her eyesight, fighting her age-related macular degeneration – a common form of … |
MedCity News |
Allergan (AGN) and Editas Tie Up to Treat Eye Diseases
Zacks.com The agreement includes early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine’s CRISPR genome editing platform, including CRISPR/Cas9 and CRISPR/Cpf1. CRISPR (Clustered Regularly Interspaced Short … Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing …GlobeNewswire (press release) Editas, Allergan Ink $90M CRISPR-Based Eye Drug DealGenomeWeb Allergan and Editas announce $90M CRISPR dealMedCity News Labiotech.eu (blog) –Pharmaceutical Executive (press release) (registration) (blog) all 109 news articles » |
Scope (blog) |
Immunotherapy may help treat kids’ brain tumors, preliminary Stanford study shows
Scope (blog) However, they hope that combining this form of immunotherapy with low doses of other cancer treatments may provide a treatment that is both more effective and less damaging than existing options. Because the anti-CD47 antibodies are already being … Targeting innate immune system shrinks pediatric brain tumorsBioWorld Online Antibody fights pediatric brain tumors in preclinical testingStanford Medical Center Report |
|
Allergan And Editas Medicine Enter Into R&D Alliance
Bio-IT World The agreement covers early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine’s CRISPR genome editing platform, including CRISPR/Cas9 and CRISPR/Cpf1. Editas Medicine’s lead program is being developed for the … Allergan (AGN) and Editas Tie Up to Treat Eye DiseasesNasdaq Allergan makes a deal with Editas to License CRISPR Programs for Eye DiseaseLabiotech.eu (blog) Allergan and Editas Medicine Enter into R&D Alliance for Eye DiseasesPharmaceutical Executive (press release) (registration) (blog) Seeking Alpha all 98 news articles » |
|
Longeveron Achieves Milestone in Groundbreaking Stem Cell Trial for Alzheimer’s Disease
PR Newswire (press release) MIAMI, March 15, 2017 /PRNewswire/ — Longeveron, a leading stem cell research company focused on biological solutions for age-associated diseases, announced today the successful completion of enrollment in the first phase of its clinical research … |